torcetrapib has been researched along with Drug-Related Side Effects and Adverse Reactions in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeLisle, RK; Ganz, P; Hyde, C; Malarstig, A; Murthy, AC; Ostroff, R; Segal, MR; Weiss, SJ; Williams, SA | 1 |
| McCabe, C; Rasko, JE; Sipp, D | 1 |
| Pfeffer, MA; Sacks, FM | 1 |
| Becker, RC | 1 |
1 review(s) available for torcetrapib and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Leapfrogging data: no shortcuts for safety or efficacy information.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Drug-Related Side Effects and Adverse Reactions; Humans; Quinolines | 2008 |
1 trial(s) available for torcetrapib and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Cholesterol Ester Transfer Proteins; Drug-Related Side Effects and Adverse Reactions; Early Diagnosis; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Proteomics; Quinolines; Stroke; Survival Analysis | 2018 |
2 other study(ies) available for torcetrapib and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Show drugs work before selling them.
Topics: Alanine; Azepines; Child; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; History, 20th Century; History, 21st Century; Humans; Iduronate Sulfatase; Models, Economic; Mucopolysaccharidosis II; Patient Safety; Pharmaceutical Preparations; Quinolines; Reproducibility of Results; Thalidomide; United States; United States Food and Drug Administration | 2017 |
Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.
Topics: Anticholesteremic Agents; Biopharmaceutics; Clinical Trials as Topic; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Endothelial Cells; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusion Pumps, Implantable; Quinolines; Stem Cells; Stents | 2007 |